• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,409.98 254.36
( 0.33%)
Global Indices
Nasdaq
51,515.27 -505.40
(-0.97%)
Dow Jones
7,441.22 -91.13
(-1.21%)
Hang Seng
71,050.31 1,148.06
(1.64%)
Nikkei 225
10,394.87 -113.74
(-1.08%)
Forex
USD-INR
94.55 -0.09
(-0.09%)
EUR-INR
109.66 -0.13
(-0.12%)
GBP-INR
126.84 -0.25
(-0.20%)
JPY-INR
0.59 0.00
(-0.20%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

thakkers group ltd
Jagsonpal Pharma sizzles as board to mull buyback proposal
Mar 10,2026
As on 31st December 2025, the company’s promoter shareholding stood at 67.39%.

Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.

The company’s standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.